Blog
RSS FeedPosted by Michael Wonder on 19 Jun 2019
Game-changing cancer drugs which can attack all tumours will be fast-tracked by NHS
19 June 2019 - Game-changing cancer drugs which can attack all types of tumour will be fast-tracked by the NHS, ...
Posted by Michael Wonder on 19 Jun 2019
NICE nod for Blincyto
19 June 2019 - NICE has announced the recommendation of Amgen’s Blincyto (blinatumomab) for treating acute lymphoblastic leukaemia. ...
Posted by Michael Wonder on 18 May 2019
NICE recommends Revlimid as multiple myeloma alternative
17 May 2019 - NICE has recommended Revlimid (lenalidomide), a drug that helps to support the immune system to fight ...
Posted by Michael Wonder on 03 May 2019
NICE recommends Roche’s Tecentriq for metastatic NSCLC
3 May 2019 - NICE has published final draft guidance recommending Roche’s Tecentriq in combination with other therapies for metastatic ...
Posted by Michael Wonder on 10 Apr 2019
Novartis’ Kisqali hit with NICE rejection
10 April 2019 - NICE has issued a draft guidance which does not recommend Novartis’ Kisqali (ribociclib), which is typically ...
Posted by Michael Wonder on 08 Apr 2019
Prostate cancer hormone therapy rejected on NHS in England
8 April 2019 - A prostate cancer drug won't be offered on the NHS any earlier in the treatment plans of ...
Posted by Michael Wonder on 07 Apr 2019
NICE appraisal for BMS kidney cancer immunotherapy combination
5 April 2019 - NICE has issued a Final Appraisal Determination endorsing NHS use of an Opdivo (nivolumab) and Yervoy ...
Posted by Michael Wonder on 02 Apr 2019
NICE nod for breast cancer delay drug
2 April 2019 - NICE has recommended Eli Lilly’s Verzenio (abemaciclib) when given with Faslodex (fulvestrant), to be available for ...
Posted by Michael Wonder on 28 Mar 2019
Promising lung cancer treatment approved for Cancer Drugs Fund
28 March 2019 - A promising new lung cancer treatment will be available on the NHS through the Cancer Drugs Fund, ...
Posted by Michael Wonder on 23 Mar 2019
NICE nod for Takeda’s Adcetris in advanced stage CTCL
22 March 2019 - Takeda has announced the NICE recommendation of its advanced cutaneous T-cell lymphoma drug Adcetris (brentuximab vedotin). ...
Posted by Michael Wonder on 21 Mar 2019
NICE terminates yet another assessment of a cancer medicine
20 March 2019 - This time it is pembrolizumab (Keytruda). ...
Posted by Michael Wonder on 20 Mar 2019
York man Paul Thomas-Peter says he could die because NHS won't fund drug
19 March 2019 - A York cancer patient says he could die because the NHS refuses to fund immunotherapy treatment ...
Posted by Michael Wonder on 14 Mar 2019
One in four cancer patients wait two months for treatment, as NHS performance hits record low
14 March 2019 - The number of cancer sufferers waiting at least two months for treatment after an urgent referral ...
Posted by Michael Wonder on 14 Mar 2019
UK breast cancer patients win early access to Tecentriq/nab-paclitaxel
14 March 2019 - Adults in the UK with PD-L1 positive, unresectable locally advanced or metastatic triple-negative breast cancer have ...
Posted by Michael Wonder on 13 Mar 2019
Cancer patient denied life-prolonging drug as she lives half a mile outside England
13 March 2019 - A seriously ill mum-of-two has spoken of her devastation after being denied a life prolonging cancer drug ...